Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13557884 | 0.81 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL13557874 | 0.77 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL21241166 | 0.74 | UHRF1 (0.42) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL13557867 | 0.74 | KDM4E (0.47) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL7048629 | 0.73 | NCF1 (0.55) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28590788 | 0.71 | NCF1 (0.53) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL5435508 | 0.70 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL30033429 | 0.69 | KDR (0.57) | RAB9ANPC1SMN1; SMN2KDM4EGAA | |
| SCHEMBL1702057 | 0.69 | KDR (0.57) | RAB9ANPC1SMN1; SMN2KDM4EGAA | |
| SCHEMBL426823 | 0.68 | UHRF1 (0.52) | RAB9ANPC1SMN1; SMN2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | disclosed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | disclosed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | disclosed |
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2017-08-10 | — | — | US | disclosed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | disclosed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | disclosed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | RAB9A 2148/4885NPC1 80/4885SMN1; SMN2 3125/4885 |
| US-10017498-B2 | Compounds useful for treating AIDS | NR1H3, NR1H2, NR1H4 | RAB9A 1953/4885NPC1 7/4885SMN1; SMN2 4057/4885 |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | RAB9A 4149/4885NPC1 45/4885SMN1; SMN2 4559/4885 |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR3C1, NR3C2 | RAB9A 2393/4885NPC1 45/4885SMN1; SMN2 4183/4885 |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR1H2, NR1H4 | RAB9A 1953/4885NPC1 7/4885SMN1; SMN2 4057/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | RAB9A 3396/4885NPC1 126/4885SMN1; SMN2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.